AI Article Synopsis

  • The study aimed to investigate the effects of empagliflozin, an SGLT2 inhibitor, on the levels of plasminogen activator inhibitor-1 (PAI-1) and fibrinolytic activity in type 2 diabetes patients, as elevated PAI-1 is linked to vascular diseases like heart disease and stroke.
  • In a trial with 51 patients, those receiving empagliflozin experienced significant reductions in body weight, visceral fat, and PAI-1 levels compared to a control group on standard therapy over 12 weeks.
  • The results suggested that the reduction in PAI-1 was related to weight loss and changes in serum leptin levels, indicating that empagliflozin may

Article Abstract

Aims: Elevation of the plasma concentration of plasminogen activator inhibitor-1 (PAI-1), a rapid-acting inhibitor of fibrinolysis, is associated with development of vascular thrombotic diseases, including coronary artery disease and stroke. We investigated the effects of empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, on the plasma concentration of PAI-1 and fibrinolytic activity in patients with type 2 diabetes.

Methods: In a randomized, active-controlled, open-label trial, 51 patients with type 2 diabetes were randomly allocated at a 2:1 ratio to receive empagliflozin (10 mg/day, n = 31) or standard therapy (n = 18) for 12 weeks. We measured the plasma concentrations of PAI-1 and plasmin-α2-antiplasmin complex (PAP) as indicators of fibrinolytic activity. Serum leptin and high-molecular weight (HMW) adiponectin were also measured.

Results: In 49 patients who completed the trial, baseline plasma PAI-1 showed a positive correlation with body weight, visceral fat area (VFA), γ-glutamyltranspeptidase (GGT), leptin, and the platelet count, while it showed a negative correlation with HDL cholesterol and PAP. Body weight and VFA decreased significantly in the empagliflozin group, but not in the control group. The serum level of GGT showed a significant decrease at 12 weeks in the empagliflozin group, while it was unchanged in the control group. Serum HMW adiponectin increased significantly in the empagliflozin group. Plasma PAI-1 decreased significantly by 25% in the empagliflozin group, but not in the control group. In the empagliflozin group, the change of plasma PAI-1 was positively correlated with the changes of body weight and leptin, but was negatively correlated with the change of PAP.

Conclusions: Empagliflozin reduced the plasma PAI-1 concentration through its synergistic actions of a glucose-lowering effect, VFA loss, and restoring the adipokine balance. (Clinical trial registry: UMIN000025418).

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdiacomp.2020.107703DOI Listing

Publication Analysis

Top Keywords

empagliflozin group
20
plasma pai-1
16
plasma concentration
12
patients type
12
body weight
12
control group
12
empagliflozin
9
plasma
8
concentration plasminogen
8
plasminogen activator
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!